DE3444765A1 - Immunmodulierendes arzneimittel - Google Patents

Immunmodulierendes arzneimittel

Info

Publication number
DE3444765A1
DE3444765A1 DE19843444765 DE3444765A DE3444765A1 DE 3444765 A1 DE3444765 A1 DE 3444765A1 DE 19843444765 DE19843444765 DE 19843444765 DE 3444765 A DE3444765 A DE 3444765A DE 3444765 A1 DE3444765 A1 DE 3444765A1
Authority
DE
Germany
Prior art keywords
fragments
igg
cells
fab
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19843444765
Other languages
German (de)
English (en)
Inventor
Jacques L'Arbresle Armand
Edgardo D. Lyon Carosella
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Merieux SA
Original Assignee
Institut Merieux SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Merieux SA filed Critical Institut Merieux SA
Publication of DE3444765A1 publication Critical patent/DE3444765A1/de
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/868—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, or immunotolerance

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
DE19843444765 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel Ceased DE3444765A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8319568A FR2556219B1 (fr) 1983-12-07 1983-12-07 Nouveau medicament immunomodulateur, a base de fragments fc d'igg humaines

Publications (1)

Publication Number Publication Date
DE3444765A1 true DE3444765A1 (de) 1985-06-20

Family

ID=9294941

Family Applications (3)

Application Number Title Priority Date Filing Date
DE19843444765 Ceased DE3444765A1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel
DE198484402531T Pending DE147283T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fe fragmenten menschlichen iggs.
DE8484402531T Expired DE3479398D1 (en) 1983-12-07 1984-12-07 Immunomodulating medicine based on fc fragments of human igg

Family Applications After (2)

Application Number Title Priority Date Filing Date
DE198484402531T Pending DE147283T1 (de) 1983-12-07 1984-12-07 Immunmodulierendes arzneimittel basiert auf fe fragmenten menschlichen iggs.
DE8484402531T Expired DE3479398D1 (en) 1983-12-07 1984-12-07 Immunomodulating medicine based on fc fragments of human igg

Country Status (7)

Country Link
US (1) US4719107A (OSRAM)
EP (1) EP0147283B1 (OSRAM)
JP (1) JPS60185726A (OSRAM)
AT (1) ATE45498T1 (OSRAM)
CA (1) CA1229791A (OSRAM)
DE (3) DE3444765A1 (OSRAM)
FR (1) FR2556219B1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016354A1 (en) * 1990-04-23 1991-10-31 3I Research Exploitation Limited Processes and intermediates for synthetic antibody derivatives

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62153300A (ja) * 1985-12-26 1987-07-08 Teijin Ltd ヒト免疫グロブリンＧＦｃ領域蛋白質およびその製造方法
US4925920A (en) * 1987-05-29 1990-05-15 Brigham And Women's Hospital Immunosuppressive polypeptides
US4814433A (en) * 1987-09-16 1989-03-21 Miles Inc. Method for obtaining a papain-free antibody fragment preparation
US5681566A (en) * 1988-10-24 1997-10-28 3I Research Exploitation Limited Antibody conjugates with two or more covalently linked FC regions
GB8824869D0 (en) * 1988-10-24 1988-11-30 Stevenson G T Synthetic antibody
FR2639231A1 (fr) * 1988-11-23 1990-05-25 Merieux Inst Utilisation de fragments fc d'immunoglobulines g humaines, de peptides analogues du fragment fc, ou d'immunoglobulines g humaines dans l'obtention d'un medicament preparatoire a l'administration chez l'homme, dans un but therapeutique ou de diagnostic, d'anticorps monoclonaux
US5328834A (en) * 1989-09-08 1994-07-12 Unisyn Technologies, Inc. Method for preparing immunoglobulin fragments
US5230887A (en) * 1990-07-11 1993-07-27 Immune Network Research Ltd. Immune system stabilizers for prevention and therapy of disorders associated with immune system disfunction
US5219578A (en) * 1991-02-25 1993-06-15 Innovet, Inc. Composition and method for immunostimulation in mammals
US7425331B2 (en) * 2002-04-10 2008-09-16 Protalex, Inc. Protein A methods of use
US7211258B2 (en) * 2002-04-10 2007-05-01 Protalex, Inc. Protein A compositions and methods of use
CA2967294C (en) * 2003-05-16 2020-04-28 Mayo Foundation For Medical Education & Research Compositions and methods including a recombinant human mab that promotes cns remyelination
DE602004031772D1 (de) * 2003-12-04 2011-04-21 Abbott Biotherapeutics Corp Anti-ip-10-antikörper
EP2455100A3 (en) * 2005-11-07 2012-11-07 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
US20080206246A1 (en) * 2006-04-05 2008-08-28 Ravetch Jeffrey V Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
US8470318B2 (en) * 2005-11-07 2013-06-25 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2815768A3 (en) * 2006-04-05 2015-01-14 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2423219B1 (en) 2007-01-30 2015-04-29 Epivax, Inc. Regulatory T cell epitopes, compositions and uses thereof
US20110150867A1 (en) * 2007-12-14 2011-06-23 The Rockefeller University Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods
EP2279410B1 (en) * 2008-04-22 2015-11-11 The Rockefeller University Methods of identifying anti-inflammatory compounds
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
WO2017151971A2 (en) 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
CA3025310A1 (en) 2016-05-23 2017-11-30 Momenta Pharmaceuticals, Inc. Compositions and methods related to engineered fc constructs
KR102624254B1 (ko) 2017-01-06 2024-01-12 모멘타 파머슈티컬스 인코포레이티드 유전자 조작 Fc 작제물에 관한 조성물 및 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928580A (en) * 1973-03-22 1975-12-23 Michel J Fontaine Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE3228007A1 (de) * 1981-07-28 1983-02-17 Dainippon Pharmaceutical Co. Ltd., Osaka Arzneimittel zur behandlung von systemischem lupus erythematodes und primaerer glomerulonephritis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2267115B1 (OSRAM) * 1974-04-12 1977-11-10 Merieux Inst
DE2853453A1 (de) * 1978-12-11 1980-06-19 Behringwerke Ag Mittel zur therapie von immunkomplexerkrankungen
JPS5821624A (ja) * 1982-04-06 1983-02-08 Tetsuzo Sugizaki 慢性関節リウマチの治療剤
DE3364347D1 (en) * 1982-04-09 1986-08-07 Fujirebio Kk Anti immune complex antibody and preparation thereof
US4465670A (en) * 1982-07-23 1984-08-14 Dainippon Pharmaceutical Co., Ltd. Method for the treatment of systemic lupus erythematosus and primary glomerulonephritis and agent therefor

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3928580A (en) * 1973-03-22 1975-12-23 Michel J Fontaine Injectable glycoproteins containing terminal {37 C{38 {0 ends of human immunoglobulins
DE2846412A1 (de) * 1978-10-25 1980-05-08 Behringwerke Ag Mittel zur behandlung allergischer reaktionen
DE3228007A1 (de) * 1981-07-28 1983-02-17 Dainippon Pharmaceutical Co. Ltd., Osaka Arzneimittel zur behandlung von systemischem lupus erythematodes und primaerer glomerulonephritis

Non-Patent Citations (17)

* Cited by examiner, † Cited by third party
Title
BERGMAN *
BERGMAN, M.A., WEIGLE, W.O.: J. Exp. Med. 146+ (1977), S. 241-256
BERMAN, M.A. et.al.: Journal. of Immunology 122 (1979), S. 89-96 *
F., GOZZE, I.: Int. Archs Allergy appl. Immun. 57(1978), S. 375-378 *
H.E. et.al.: Clin. exp. Immunol. 37 (1979), S. 162-168 *
J.T.: Vox Sang. 13 (1967), S. 71-84 *
M.A., WEIGLE, W.O.: J. Exp. Med. 146+ (1977), S. 241-256 *
MORGAN, E.L. et.al.: Exp. Med. 152, (1980), S. 113-123 *
MORGAN, E.L. et.al: J. Exp. Med. 153 (1981), S. 1161-1172 *
MORGAN,E.L., WEIGLE, W.O.: J. Exp. Med. 154 (1981), S. 778-790 *
PASSWELL, J.H. et.al.: Immunology 41 (1980), S. 217-225 *
PRINCE *
PRINCE, H.E. et.al.: Clin. exp. Immunol. 37 (1979), S. 162-168
SGOURIS *
SGOURIS J.T.: Vox Sang. 13 (1967), S. 71-84
SKVARIL *
SKVARIL F., GOZZE, I.: Int. Archs Allergy appl. Immun. 57(1978), S. 375- 378

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991016354A1 (en) * 1990-04-23 1991-10-31 3I Research Exploitation Limited Processes and intermediates for synthetic antibody derivatives
US6136313A (en) * 1990-04-23 2000-10-24 Imperial College Innovations Limited Processes and intermediates for synthetic antibody derivatives

Also Published As

Publication number Publication date
FR2556219A1 (fr) 1985-06-14
ATE45498T1 (de) 1989-09-15
FR2556219B1 (fr) 1987-06-26
JPS60185726A (ja) 1985-09-21
US4719107A (en) 1988-01-12
CA1229791A (fr) 1987-12-01
EP0147283A2 (fr) 1985-07-03
DE3479398D1 (en) 1989-09-21
DE147283T1 (de) 1986-04-10
EP0147283A3 (en) 1985-08-14
EP0147283B1 (fr) 1989-08-16
JPH0586378B2 (OSRAM) 1993-12-10

Similar Documents

Publication Publication Date Title
DE3854741T2 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
DE3812595C2 (de) Verwendung einer 17-Ketosteroid-Verbindung zur Prophylaxe und Therapie von Retrovirus-Infektionen
US4719107A (en) Immunomodulating medication based on Fc fragments of human IgG
DE69905368T2 (de) Oxydiertes thymosin beta 4
DE2628914C2 (OSRAM)
DE69507123T2 (de) Prophylaktische verbindungen gegen aids und sle
EP0346501B1 (de) Arzneimittelzubereitung zur behandlung des immunmangels
DE69133225T2 (de) Regulierung der immunoglobulinproduktion durch interleukin-9
EP1600164A2 (de) Verwendung einer an CD28 bindenden Wirksubstanz zur Herstellung einer Pharmazeutischen Zusammensetzung mit dosisabhängiger Wirkung
EP0170099B1 (de) Verwendung von Lycorin als Immunsuppressor
DE69816796T2 (de) Pharmazeutische oder nahrungsmittelzusammensetzung für die behandlung von pathologien die assoziiert sind mit einem transplantatabstoss, einer allergischen oder autoimmunreaktion
EP0358130B1 (de) Mittel mit immunsuppressiver Wirkung
DE3688337T2 (de) Polypeptidfaktoren aus Kolostrum.
DE3752184T2 (de) Herstellung und Verwendungen von gamma-Interferon
DE68912582T2 (de) Anti-hiv-mittel.
DE69122764T2 (de) Arznei gegen hornhautbeschädigungen
EP0951481B1 (de) Verwendung von substanzen mit immunmodulatorischer wirkung für die behandlung der amyotrophen lateralsklerose
EP0183253B1 (de) Arzneimittel enthaltend einen aus den Peyer'schen Plaques hergestellten Organextrakt zur Behandlung bei Diabetes Mellitus und Pankreatitis
DE2610854A1 (de) Galenische immunglobulinzubereitung
EP0505414B1 (de) Eliminierung von aktivierten lymphozyten
DE60118409T2 (de) Herstellungsverfahren von immunglobulinen, die gegen menschliche thymozyten gerichtet sind
EP0277160A1 (de) Immunsuppressivum und verfahren zu dessen herstellung
DE69434256T2 (de) Immunglobulin-Infusion bei der Xenotransplantation
DE2708780A1 (de) Neue blutserumpraeparationen, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel und medizinische hilfsstoffe
DE4435525C2 (de) Präparat zur Behandlung von Entmarkungsenzephalitiden

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8131 Rejection